Preferences & Treatment Satisfaction Drivers in Rosacea Patients
NCT ID: NCT02602470
Last Updated: 2020-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
206 participants
OBSERVATIONAL
2015-01-08
2016-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea
NCT03193372
Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study
NCT02147691
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
NCT02393937
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
NCT01257919
A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea
NCT03287791
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rosacea treated patients
Patients using topical rosacea treatment
Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)
Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing
Azelaic Acid Cream
Azelaic Acid Cream 20%
Metronidazole gel
Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
Metronidazole cream
Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
Metronidazole Emulsion
Metronidazole Emulsion 0.75%
Metronidazole Lotion
Metronidazole Lotion 0,75%
Brimonidine Tartrate Gel
Brimonidine Tartrate Gel 0.33%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)
Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser \& Moisturizing
Azelaic Acid Cream
Azelaic Acid Cream 20%
Metronidazole gel
Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
Metronidazole cream
Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
Metronidazole Emulsion
Metronidazole Emulsion 0.75%
Metronidazole Lotion
Metronidazole Lotion 0,75%
Brimonidine Tartrate Gel
Brimonidine Tartrate Gel 0.33%
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least one prescription for a topical rosacea treatments: Azelaic Acid Gel, Azelaic Acid Cream, Metronidazole Gel, Metronidazole Cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel
* At least one medical record with a diagnosis code for rosacea (ICD-9: 695.3)
* At least 6 months of data history prior to the index date
* Had at least one encounter at the Reliant Medical Group within 3 months prior to 01 January 2015
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
LEO Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18575
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.